anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our study follows a prospective cohort study design without randomization or blinding. 20 patients undergoing unilateral hip or knee replacement will be recruited and stratified into 2 groups (each with 10 patients) with either glomerular filtration rate (GFR) \< 60 mL/min/1.73m2 (and dialysis) or GFR ≥ 60 mL/min/1.73m2. This GFR cut-off was chosen based on previous data showing low variability at GFR below and above 60, and plasma TXA levels differed due to reduction in TXA clearance rates between patients in each group.

After spinal/regional or general anesthesia, a single intravenous bolus of 20 mg/kg TXA will be administered (as per our standard of care) over 15 minutes. Serial 4-5 ml blood samples will be drawn at: baseline/pre-TXA administration, 5 min, 15 min, 30 min, 1h, 1.5h, 2h, 6h+/-2h and 12h+/-4h post-bolus. These time points capture 2-3 TXA half-lives, including peak and end of surgery (average 2 h) concentrations.

Each blood sample will be collected into standard citrate collection tubes. Tubes will be inverted a minimum of 5 times to ensure proper mixing with anti-coagulant (sodium citrate). Each sample will be labeled with an anonymized patient study number (to de-identify patient information) and sample time. The tubes will be stored on ice bath following sample collection and then centrifuged within 2 hours at 2000g for about 15 min at 4˚C. The subsequent supernatant will be frozen and stored at -70˚C until analyzed. Measurement of TXA and other drug concentrations, renal biomarkers and metabolomics will be performed using liquid chromatography-tandem mass spectroscopy (LC-MS/MS) using previously described methodology. Patients will otherwise receive routine perioperative care. Patient follow up will be to hospital discharge.
Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
The present invention relates to a process that yields a product that can suitably be used in the treatment and prevention of diarrhea without giving rise to any undesirable side-effects. The invention is based on the discovery that aqueous fractions obtained from the fermentation of certain plant materials with fungi, may effectively be used to prevent, manage and/or treat diarrhea. Thus, in one aspect, the invention relates to a process for the manufacture of a health promoting product, said process comprising the subsequent steps of: a) preparing a substrate containing from 30 to 60 wt. % dry matter of which at least 50 wt. % is derived from a plant material selected from legume, pulses, fruit, nuts, beans, seeds, grain, tubers and mixtures thereof, said substrate containing between 7.5 and 70% protein, between 20 and 67% carbohydrates and less than 40% lipids by weight of dry matter, b) inoculating said substrate with a specified fungus, c) allowing the fungus to ferment the substrate for at least 6 hours at a temperature in excess of 25° C., d) isolating an aqueous fraction from the fermentate so obtained, e) drying said aqueous fraction so as to obtain a powder which expresses at least 10 U/g of protease activity. Another aspect of the present invention relates to a composition for use in a method of treating diarrhea, wherein said method comprises administering an effective amount of a powder obtained by the process as described above.
Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
Clinical Presentation

There is limited clinical experience with milnacipran hydrochloride overdose in humans. In clinical trials, cases of acute ingestions up to 1000 mg, alone or in combination with other drugs, were reported with none being fatal.

In post-marketing experience, fatal outcomes have been reported for acute overdoses primarily involving multiple drugs but also with milnacipran hydrochloride only. The most common signs and symptoms included increased blood pressure, cardio-respiratory arrest, changes in the level of consciousness (ranging from somnolence to coma), confusional state, dizziness, and increased hepatic enzymes.

Management of Overdose

There is no specific antidote to milnacipran hydrochloride, but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug.

Ensure adequate airway, oxygenation, and ventilation and monitor cardiac rhythm and vital signs. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Because there is no specific antidote for milnacipran hydrochloride, consider symptomatic care and treatment with gastric lavage and activated charcoal as soon as possible for patients who experience a milnacipran hydrochloride overdose.

Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial.

In managing overdose, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians’ Desk Reference (PDR).
During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
Stroke has been considered one of the main causes of long-term disability in the adult population, and is no longer considered a disease of the elderly, since 2/3 of all strokes occur among people under 70 years of age. According to the Ministry of Health, stroke is responsible for 40% of early retirements, being one of the most important causes of mortality in Brazil. Stroke usually causes long-term deficits such as asymmetrical muscle weakness between limbs, impaired proprioceptive ability, sensory loss, vision problems, and spasticity. In addition, these sensorimotor deficits interfere with various functions of the lower limbs, including balance, postural control, and gait ability, affecting their quality of life. The electroencephalogram (EEG) has been shown to be a very useful tool in the study of functional status and for the diagnosis of brain damage and disorders. It is considered a simple, non-invasive test with high temporal resolution, being a method widely used in laboratories to non-invasively monitor brain activity. Microstates reflect short periods (\~100 ms) of nearly stable brain states evolving over time, resulting from the synchronous and coordinated activity of brain networks. The aim of this study is to observe whether EEG microstates have correlations with clinical characteristics of people with stroke.
The effects of LOVAZA 4 grams per day were assessed in 2 randomized, placebo-controlled, double-blind, parallel-group trials of 84 adult subjects (42 on LOVAZA, 42 on placebo) with very high triglyceride levels. Subjects whose baseline triglyceride levels were between 500 and 2,000 mg per dL were enrolled in these 2 trials of 6 and 16 weeks’ duration. The median triglyceride and LDL-C levels in these subjects were 792 mg per dL and 100 mg per dL, respectively. Median HDL-C level was 23.0 mg per dL.

The changes in the major lipoprotein lipid parameters for the groups receiving LOVAZA or placebo are shown in Table 2.

BL = Baseline (mg per dL); % Change = Median Percent Change from Baseline; Difference = LOVAZA Median % Change – Placebo Median % Change.  


LOVAZA 4 grams per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with LOVAZA to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively.

The effect of LOVAZA on the risk of pancreatitis has not been determined.

The effect of LOVAZA on cardiovascular mortality and morbidity has not been determined.
Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
The control arm will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). The patients will undergo 2 MRI scans but their results will be shared with the patients after 12 months has elapsed. They will receive standard care treatment not informed by the TransiCap results.
Patients with chronic kidney disease (CKD) are at a high risk of cardiovascular (CV) complications. In these patients, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce CV events. Mineralocorticoid receptor antagonists (MRAs) exert similar benefits in diabetic CKD, though their effects in non-diabetic CKD remain unclear. This study aimed to evaluated whether the combination of Dapagliflozin (DAPA) and Eplerenone (EPLE) would have positive effects on cardiorenal functions in a non-diabetic CKD model. CKD was induced in rats via 5/6 nephrectomy, followed by treatment with DAPA (5 mg/kg/day PO), EPLE (100 mg/kg/day PO) or the combination for 3 months following CKD induction. Cardiorenal functions were assessed after the treatment period. All treated groups showed reduced kidney fibrosis though plasma creatinine and urea levels remained unchanged. Compared to untreated CKD, EPLE or DAPA/EPLE reduced left ventricle (LV) end-diastolic pressure and LV end-diastolic pressure volume relationship, whereas DAPA alone did not achieve significant reductions. Compared to untreated CKD, EPLE and DAPA/EPLE improved cardiac perfusion but DAPA alone did not. Cardiac fibrosis in CKD was blunted by either DAPA or EPLE alone, with the combination showing an additive effect. In conclusion, co-treatment with DAPA and EPLE enhances diastolic function, cardiac perfusion and reduces myocardial fibrosis in non-diabetic CKD rats.
An illustrative method includes receiving, from a requestor device, a request to read, write, edit, or delete a resource data. The request is formatted according to a Fast Healthcare Interoperability Resources (FHIR) standard and FHIR extensions embodying an healthcare provider directory (HPD) standard. The method further includes generating an application program interface (API) request configured for a customer relationship management (CRM) database to request the read, write, edit, or delete of the resource data. The method further includes sending the API request to the CRM database. The CRM database is configured to receive a plurality of request types. The method further includes receiving, from the CRM database, data responsive to the API request. The method further includes generating data responsive to the request from the data responsive to the API request. The method further includes sending the data responsive to the request.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to composition of bis-phosphonic acids for wet granulation and method of their preparing. Pharmaceutical compositions of bis-phosphonic acids and their salts are obtained by technology of wet granulation of tablet formulas. These compositions are prepared without addition of binding agent using drug as binding agent. Invention provides treatment of patients with pathological disorders associated with metabolism of calcium or phosphorus, in part, for treatment and prophylaxis of diseases related with osseous resorption. EFFECT: improved method of preparing, valuable therapeutical properties of composition. 25 cl, 3 tbl
T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
NEW MATERIAL:A human-human hybridoma producing a human monoclonal antibody reactive at least with I-serotype Pseudomonas aeruginosa, a cell strain originated from the hybridoma and a human monoclonal antibody reactive with I-serotype Pseudomonas aeruginosa. USE:An agent for the prevention and remedy of infectious diseases with Pseudomonas aeruginosa. PREPARATION:For example, B-cell is separated from the peripheral blood of a patient having anamnesis of infection with Pseudomonas aeruginosa and fused with a parent cell strain MP4109 for the preparation of hybridoma using polyethylene glycol. The fused cell is cultured in HAT medium and the obtained hybridoma is screened to select a clone capable of producing an antibody against I-serotype Pseudomonas aeruginosa. The clone is cloned by limiting dilution analysis, etc., to obtain a human-human hybridoma reactive with I-serotype Pseudomonas aeruginosa. A human monoclonal antibody is produced by culturing the hybridoma.
FIELD: medicine, pharmaceutical industry. SUBSTANCE: invention relates to medicinal forms containing cytokines. An antiviral, antibacterial and anticandidosis agent comprises cytokines, stabilizing agent of resistance against bacterial contamination, glycerol and special additions. Agent can comprise additionally the following components: antioxidant, immunomodulating agent, antibacterial or protozoicide or antifungal agent, vitamins, anti-inflammatory preparation, topical anesthetic, riboxin. EFFECT: expanded assortment of agents with antiviral, antibacterial and anticandidosis effect. 21 cl, 11 tbl
An immune-peroxidase test for serologic diagnostics of porcine circovirus includes inoculation of the cells of sensitive culture to 96-well plastic microplates with flat bottom; dilution of test serums by the method of two-fold dilution with addition of working dilution of circovirus type 2 in the 96-well plastic microplates with round bottom with following contact of those and with bringing to the wells of the microplate with mono-layer of cell culture; incubation during seven days under conditions of COincubator; removal from the microplate wells of the culture medium, with washing the cell mono-layer; introduction of fixing buffer to all the microplate wells; step-by-step introduction to all the microplate wells – working dilution of specific blood serum, working dilution of conjugate, solution of substrate; termination of reaction through adding stop-solution to each well of the table and registration of reaction under inverted light microscope based on the principle of presence or absence of specific dyeing of the cells – infected cells look like single cells or groups of cells (plaques) with cytoplasm dyed to dark-red color and light nucleus. The test is used for reveal of specific humoral antibodies against the circovirus type 2 in domestic and wild hog through investigation of biological material (serum of blood, milk, colostrums); for cultivation sensitive to circovirus type 2 cell cultures (SK-6, RPK-15, PSGK) are used; grown in cultural vessels (glass or plastic pads) cell monolayer is taken by means of solution of trypsin-versen at ratio of 1:9. For cultivation of cell culture, 7-10 % of embryo blood serum of cattle is added to nutrient media; the test blood serums before investigation undergo inactivation at temperature during 30 minutes with titration with the method of double dilution with adding working dilution 1000 U of circovirus type 2 (reference - " Stoon 1010" or deposited strains) with exposition during one hour at +. Introduction of content to the cells of the plate with sensitive cell culture is performed at partial formation of mono-layer of those (50 %) with addition of 2 % embryo serum of cattle blood. The reference or deposited strains of circovirus type 2 are used as control virus. At fixation of mono-layer of cells 96 % ethyl alcohol is used. Porcine specific blood serum against the circovirus type 2 is used as working dilution of positive serum. The Tween-20 is not used while monolayer washing. At termination of reaction - NaCL; all manipulations with drying the cell monolayer are carried out under conditions of thermostat at temperature and exposition – one hour. When recording the reaction the presence of plaque – absence of antibodies, and the absence of plaque – presence of anti-bodies against circovirus type 2 in porcine blood serum are taken into account:.
The utility model discloses a paste forming apparatus. The utility model is characterized in that the apparatus comprises a bearing material axis(17)(11), a feeder(1), a cooling tunnel(6), a conveying belt(8)and longitudinal and transverse slitting knives(12, 13). The bearing material axis is respectively provided with a non-woven cloth tube and a silica gel cloth tube. A heater 1 is a water-jacket type double-layer structure. A refrigerating unit(16)and a blower(7)are arranged in the cooling tunnel. A silica gel cloth(B)through a guide roll(10)is movably connected with a rubber roll(9). The end of the apparatus is provided with the longitudinal slitting knife(12)being able to regulate the width and the transverse slitting knife(13)being able to regulate the width. The utility model can cause the gel type chinese and western medicine to be pasted on one apparatus and the model finishes various working operations with the complete automation. The labor intensity of the workmen is reduced and the production efficiency is raised. The paste forming apparatus of the utility model can generate the good economic benefit and the positive using effect on the manufacturer of the paste.
OBJECTIVES: To assess the association between frailty and oral health services use in Brazilian older adults.
METHODS: This cross-sectional study analysed the baseline data from the Longitudinal Study on Brazilian Ageing (ELSI-Brazil) representative of Brazilians aged 50 or over. The outcome was oral health services used in the year prior to the interview. The main exposure variable was Frailty defined by the frailty phenotype. Age, skin colour, wealth, sex, education, type of service, health insurance, number of teeth and self-perceived oral health were included as covariates. Prevalence ratios (PR) with their respective 95% confidence intervals (CI) were estimated using Poisson regression with robust variance.
RESULTS: 8405 individuals were included in this study. The prevalence of frailty was 7.5%. Regarding frailty status, the prevalence of dental service use was 47.0%, 48.5% and 4.5% for robust, pre-frail and frail individuals, respectively. Frail individuals had a 7% higher prevalence of not using dental (PR: 1.07; 95% CI: 1.01-1.13) than robust individuals. Frailty was independently associated with not using oral health services.
CONCLUSION: Given the complexity of the determinants of dental service use, frailty adds another dimension to be examined in older adults. Public health strategies considering a common risk factor approach should be endorsed.
OBJECTIVES: To evaluate the association between surgical modality (RARC vs. ORC) and the risk of 30-day complications.
MATERIALS AND METHODS: We utilized the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) Cystectomy-Targeted database from 2019 to 2021. The primary outcome was a composite of major complications including 30-day mortality, reoperation, cardiac events, and stroke. Secondary outcomes included individual major and cystectomy-specific complications. Propensity score matching (PSM) was employed to minimize inherent differences within our cohort. We performed logistic regression to assess the association between outcomes of interest and operative modality.
RESULTS: We found no difference between operative modality and the primary outcome, however, RARC was associated with a 70% lower risk of 30-day mortality (OR 0.30, 95% CI 0.13-0.70) and had favorable outcomes with respect to respiratory, deep venous thrombosis, wound complications, and length of stay. Limitations are related to residual confounding given the observational methodology.
CONCLUSIONS: RARC was associated with reduced risk of multiple 30-day complications, including mortality, as well as organ system and cystectomy-specific outcomes. These data support the clinical benefit of increased adoption of RARC.
Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
An oral dosage form of a pharmaceutical composition for managing diabetes in a subject is provided, which comprises a core, a controlled membrane film, and an outer film. The core comprises a first antidiabetic agent. The controlled membrane film coats the core tablet and can realize a controlled release of the first antidiabetic agent from the core into a portion of a digestive tract of the subject corresponding to a stomach and an upper gastrointestinal tract after the pharmaceutical composition is orally administered to the subject. The controlled membrane film comprises at least one controlling polymer, each selected from an Eudragit polymer, an Aquacoat polymer, or an Ethocel polymer. The outer film comprises a second antidiabetic agent, and coats the controlled membrane film. A method for manufacturing an oral dosage form of a pharmaceutical composition is also provided.
Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.